Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Martens AWJ, Janssen SR, Derks IAM, *et al.* CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. *J Immunother Cancer* 2020;8:e000218. doi: 10.1136/jitc-2019-000218

This paper has been updated since first published to update Figure 5L. One patient was removed from the figure since the patient originally labeled as chronic lymphocytic leukemia, has been recently re-diagnosed as indolent CD5 +mantle cell lymphoma.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2021;9:e000218corr1. doi:10.1136/jitc-2019-000218corr1